Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets

Summary

GBI Research has released its latest research “Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets”, which essentially provides insights into diabetes therapeutics sales and price forecasts until 2016. The report also examines the global diabetes therapies treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2016 are included. The report provides an in-depth analysis of HIV, Hepatitis, Herpes and Influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

According to the study done by GBI Research, the HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiry of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics, which currently account for approximately 8% of the market. The global HIV therapeutics market is expected to grow at a CAGR of 4.5% between 2008 and 2015.

Scope

- Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the diabetes therapeutics market from 2001 to 2009, with forecasts to 2016.
- Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi-Aventis, Takeda Pharmaceuticals, Merck, GlaxoSmithKline, Roche, Bristol Myers Squibb and Gilead.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.

Table Of Contents

1 Table of Contents 5
1.1 List of Tables 10
1.2 List of Figures 14
2 Global Antivirals Market: Introduction 17
2.1 GBI Research Report Guidance 17
3 Global HIV Therapeutics Market: Overview 18
3.1 Disease Overview 18
3.2 Market Overview 19
4 Global HIV Therapeutics Market: Market Characterization 20
4.1 Market Forecasts 20
4.2 Annual Cost of Therapy 21
4.3 Usage Patterns 23
4.3.1 Diseased Population 23
4.3.2 Treatment Seeking Population 25
4.3.3 Diagnosis Population 27
4.3.4 Prescription Population 29
4.3.5 Usage Patterns 31
4.3.6 Geographical Distribution 33
4.4 HIV Therapeutics Market: Drivers and Restraints 34
4.5 Market Drivers 34
4.5.1 Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population 34
4.5.2 New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake 35
4.5.3 Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering the Impact of Generics 36
4.6 Market Restraints 37
4.6.1 Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions 37
4.6.2 Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base 38
4.6.3 Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes 38
5 Global HIV Therapeutics Market: The US Market 39
5.1 Market Forecasts 39
5.2 Annual Cost of Therapy 41
5.3 Usage Patterns 42
5.3.1 Diseased Population 42
5.3.2 Treatment Seeking Population 44
5.3.3 Diagnosis Population 45
5.3.4 Prescription Population 47
5.3.5 Usage Patterns 49
6 Global HIV Therapeutics Market: Europe Market 51
6.1 Market Forecasts 51
6.2 Annual Cost of Therapy 53
6.3 Usage Patterns 55
6.3.1 Diseased Population 55
6.3.2 Treatment Seeking Population 56
6.3.3 Diagnosis Population 58
6.3.4 Prescription Population 60
6.3.5 Usage Patterns 61
7 Global HIV Therapeutics Market: Japan Market 63
7.1 Market Forecasts 63
7.2 Annual Cost of Therapy 65
7.3 Usage Patterns 66
7.3.1 Diseased Population 66
7.3.2 Treatment Seeking Population 67
7.3.3 Diagnosis Population 68
7.3.4 Prescription Population 69
7.3.5 Usage Patterns 70
8 Global HIV Therapeutics Market: Major Drug Classes 72
8.1 Different Classes of Drugs 72
8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 72
8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 73
8.1.3 Protease Inhibitors 74
8.1.4 Viral Fusion (or Entry) Inhibitors 74
8.1.5 HIV Integrase Strand Transfer Inhibitors 74
8.1.6 Multi-class Combination Products 74
8.2 Pipeline Analysis 75
8.2.1 Phase I 76
8.2.2 Phase II 84
8.2.3 Phase III 97
9 Global Hepatitis Therapeutics Market: Market Overview 105
9.1 Introduction 105
9.2 Revenue Forecasts for the Global Hepatitis Therapeutics Market 106
9.2.1 Sales Value 106
9.2.2 Annual Cost of Therapy 107
9.2.3 Treatment Usage Patterns 108
9.3 Hepatitis Market Drivers 114
9.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline 114
9.3.2 Promising Developments in the Hepatitis C Pipeline 114
9.3.3 Steady Increase in Prescription Population 114
9.4 Hepatitis Market Restraints 115
9.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms During the Acute Phase 115
9.4.2 Low Treatment Seeking Population 115
9.4.3 Loss of Exclusivity Protection in Hepatitis B Market 115
9.5 Generic Share in the Global Hepatitis Market 116
10 Global Hepatitis Market: Therapeutic Landscape 117
10.1 Introduction 117
10.1.1 Hepatitis A 117
10.1.2 Hepatitis B 117
10.2 Overview of Hepatitis A and B Vaccines Market 117
10.2.1 Sales Value 118
10.3 Hepatitis B Market 119
10.3.1 Introduction 119
10.3.2 Sales Value 120
10.3.3 Annual Cost of Therapy 121
10.3.4 Treatment Usage Patterns 122
10.3.5 Geographical Segmentation 127
10.4 Hepatitis C Market 129
10.4.1 Introduction 129
10.4.2 Sales Value 130
10.4.3 Annual Cost of Therapy 131
10.4.4 Treatment Usage Patterns 132
10.4.5 Geographical Segmentation 138
11 Global Hepatitis Market: Geographical Landscape 141
11.1 Geographical Break-up 141
11.2 The US 144
11.2.1 Sales Value 144
11.2.2 Annual Cost of Therapy 145
11.2.3 Treatment Usage Patterns 146
11.3 Top Five Countries in Europe 152
11.3.1 Sales Value 152
11.3.2 Annual Cost of Therapy 154
11.3.3 Treatment Usage Patterns 155
11.4 Japan 160
11.4.1 Sales Value 160
11.4.2 Annual Cost of Therapy 161
11.4.3 Treatment Usage Patterns 162
11.5 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis 168
11.6 Introduction 168
11.6.1 Research and Development Pipeline - Hepatitis B Therapeutics 171
11.6.2 Research and Development Pipeline - Hepatitis C Therapeutics 176
12 Herpes Simplex Therapeutics Market: Market Characterization 191
12.1 Overview 191
12.2 Herpes Simplex Therapeutics Market Size 192
12.3 Herpes Simplex Therapeutics Market Forecast and CAGR 193
12.4 Drivers and Barriers for the Herpes Simplex Therapeutics Market 194
12.4.1 Drivers for the Herpes Simplex Therapeutics Market 194
12.4.2 Barriers for the Herpes Simplex Therapeutics Market 194
12.5 Herpes Simplex Therapeutics Market: Competitive Assessment 195
12.6 Overview 195
12.7 Strategic Competitor Assessment 195
12.8 Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market 196
12.8.1 Zovirax (Acyclovir) 196
12.8.2 Famvir (Famciclovir) 197
12.8.3 Valtrex (Valacyclovir) 198
13 Herpes Simplex Therapeutics Market: Pipeline Assessment 201
13.1 Overview 201
13.2 Herpes Simplex Therapeutics - Promising Drugs under Clinical Development 201
13.3 Molecule Profiles for Promising Drugs under Clinical Development 201
13.3.1 BA-021 (Acyclovir Lauriad) 201
13.3.2 RPI-78M 202
13.3.3 AIC316 202
13.4 Herpes Simplex Therapeutics Market - Pipeline Assessment by Mechanism of Action 203
13.5 Herpes Simplex Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 204
13.5.1 Herpes Simplex Therapeutics - Phase III Clinical Pipeline 204
13.5.2 Herpes Simplex Therapeutics - Phase II Clinical Pipeline 205
13.5.3 Herpes Simplex Therapeutics - Phase I Clinical Pipeline 205
13.5.4 Herpes Simplex Therapeutics - Preclinical Pipeline 206
14 Global Influenza Therapeutics Market: Overview 207
14.1 Disease Overview 207
14.2 Influenza 207
14.3 Market Overview 208
15 Global Influenza Therapeutics Market: Market Characterization 209
15.1 Market Forecasts 209
15.2 Annual Cost of Therapy 210
15.3 Usage Patterns 211
15.3.1 Diseased Population 211
15.3.2 Treatment Seeking Population 212
15.3.3 Diagnosis Population 213
15.3.4 Usage Patterns 214
15.3.5 Geographical Distribution 215
16 Global Influenza Therapeutics Market: The US Market 216
16.1 Market Forecasts 216
16.2 Annual Cost of Therapy 217
16.3 Usage Patterns 218
16.3.1 Diseased Population 218
16.3.2 Treatment Seeking Population 219
16.3.3 Diagnosis Population 220
16.3.4 Prescription Population 221
16.3.5 Usage Patterns 222
17 Global Influenza Therapeutics Market: Europe Market 224
17.1 Market Forecasts 224
17.2 Annual Cost of Therapy 225
17.3 Usage Patterns 226
17.3.1 Diseased Population 226
17.3.2 Treatment Seeking Population 227
17.3.3 Diagnosis Population 228
17.3.4 Prescription Population 229
17.3.5 Usage Patterns 230
18 Global Influenza Therapeutics Market: Japan Market 232
18.1 Market Forecasts 232
18.2 Annual Cost of Therapy 233
18.3 Usage Patterns 234
18.3.1 Diseased Population 234
18.3.2 Treatment Seeking Population 235
18.3.3 Diagnosis Population 236
18.3.4 Prescription Population 237
18.3.5 Usage Patterns 238
19 Pipeline Analysis 240
19.1.1 Phase I 240
19.1.2 Phase II 242
19.1.3 Phase III- Major Pipeline Products and their Mechanisms of Action 245
20 Antivirals Market- Competitive Landscape 247
20.1 Global HIV/AIDs Market: Competitive Landscape 247
20.2 Major Company Profiles 249
20.2.1 Gilead 250
20.2.2 GlaxoSmithKline (GSK) 251
20.2.3 Bristol-Myers Squibb (BMS) 253
20.2.4 Abbott Laboratories 254
20.2.5 Merck 256
20.2.6 Pfizer 257
20.3 Global Hepatitis Therapeutics Market- Competive Landcape 258
20.4 Major Company Profiles 260
20.4.1 Merck and Co., Inc. 260
20.4.2 F. Hoffmann-La Roche Ltd. 263
20.4.3 GlaxoSmithKline plc 265
20.5 Global Herpes Simplex Market: Competitive Landscape 267
20.6 Major Company Profiles 267
20.6.1 BioAlliance Pharma 268
20.6.2 Nutra Pharma Corporation 269
20.6.3 AiCuris GmbH and Co. KG 270
21 Global Antivirals Therapeutics Market: Strategic Consolidations 271
21.1 Global HIV/AIDS Market 271
21.1.1 Overview: Deals by Type and Geography 271
21.1.2 Mergers and Acquisitions 272
21.1.3 Licensing Agreements 274
21.2 Global Hepatitis Market 278
21.2.1 Overview: Deals by Type and Geography 278
21.2.2 Mergers and Acquisitions 279
21.2.3 Licensing Agreements 280
21.3 Global Herpes Market 285
21.3.1 Mergers and Acquisitions 285
21.3.2 Licensing Agreements 286
21.4 Global Influenza Therapeutics Market 286
21.4.1 Mergers and Acquisitions 286
21.4.2 Licensing Agreements 287
22 Antivirals Market: Appendix 289
22.1 Market Definitions 289
22.2 Abbreviations 289
22.3 Research Methodology 292
22.3.1 Coverage 292
22.3.2 Secondary Research 292
22.3.3 Primary Research 293
22.3.4 Forecasts 293
22.3.5 Expert Panel Validation 296
22.4 Contact Us 296
22.5 Disclaimer 296
22.6 Sources 296

1.1 List of Tables
Table 1: HIV Therapeutics Market, Global, Revenue ($m), 2001-2009 20
Table 2: HIV Market, Global, Revenue ($m), 2009-2016 20
Table 3: HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 22
Table 4: HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 22
Table 5: HIV Therapeutics Market, Global, Diseased Population(‘000), 2001-2009 24
Table 6: HIV Therapeutics Market, Global, Diseased Population(‘000), 2009-2016 24
Table 7: HIV Therapeutics Market, Global, Treatment Seeking Population(‘000), 2001-2009 25
Table 8: HIV Therapeutics Market, Global, Treatment Seeking Population(‘000), 2009-2016 25
Table 9: HIV Therapeutics Market, Global, Diagnosis Population, 2001-2009 28
Table 10: HIV Therapeutics Market, Global, Diagnosis Population, 2009-2016 28
Table 11: HIV Therapeutics Market, Global, Prescription Population, 2001-2009 30
Table 12: HIV Therapeutics Market, Global, Prescription Population, 2009-2016 30
Table 13: HIV Therapeutics Market, Global, Usage Patterns(‘000), 2001-2009 32
Table 14: HIV Therapeutics Market, Global, Usage Patterns(‘000), 2009-2016 32
Table 15: HIV Therapeutics Market, Global, Key Drug Going Off Patent, 2009-2016 37
Table 16: HIV Therapeutics Market, US, Revenues ($m), 2001-2009 40
Table 17: HIV Therapeutics Market, US, Revenue ($m), 2009-2016 40
Table 18: HIV Therapeutics Market, US, Annual Average Cost of Therapy ($), 2001-2009 41
Table 19: HIV Therapeutics Market, US, Annual Average Cost of Therapy ($), 2009-2016 41
Table 20: HIV Therapeutics Market, US, Diseased Population(‘000), 2001-2009 43
Table 21: HIV Therapeutics Market, US, Diseased Population(‘000), 2009-2016 43
Table 22: HIV Therapeutics Market, US, Treatment Seeking Population(‘000), 2001-2009 44
Table 23: HIV Therapeutics Market, US, Treatment Seeking Population(‘000), 2009-2016 44
Table 24: HIV Therapeutics Market, US, Diagnosis Population(‘000), 2001-2009 46
Table 25: HIV Therapeutics Market, US, Diagnosis Population(‘000), 2009-2016 46
Table 26: HIV Therapeutics Market, US, Prescription Population(‘000), 2001-2009 48
Table 27: HIV Therapeutics Market, US, Prescription Population(‘000), 2009-2016 48
Table 28: HIV Therapeutics Market, US, Usage Patterns(‘000), 2001-2009 50
Table 29: HIV Therapeutics Market, US, Usage Patterns(‘000), 2009-2016 50
Table 30: HIV Therapeutics Market, Europe, Revenues ($m), 2001-2009 52
Table 31: HIV Therapeutics Market, Europe, Revenue ($m), 2009-2016 52
Table 32: HIV Therapeutics Market, Europe, Average Cost of Treatment($), 2001-2009 54
Table 33: HIV Therapeutics Market, Europe, Average Cost of Treatment($), 2009-2016 54
Table 34: HIV Therapeutics Market, Europe, Diseased Population(’00), 2001-2009 55
Table 35: HIV Therapeutics Market, Europe, Diseased Population(’00), 2009-2016 55
Table 36: HIV Therapeutics Market, Europe, Treatment Seeking Population(’00), 2001-2009 57
Table 37: HIV Therapeutics Market, Europe, Treatment Seeking Population(’00), 2009-2016 57
Table 38: HIV Therapeutics Market, Europe, Diagnosis Population(’00), 2001-2009 59
Table 39: HIV Therapeutics Market, Europe, Diagnosis Population(’00), 2009-2016 59
Table 40: HIV Therapeutics Market, Europe, Prescription Population(’00), 2001-2009 60
Table 41: HIV Therapeutics Market, Europe, Prescription Population(’00), 2009-2016 60
Table 42: HIV Therapeutics Market, Europe, Usage Patterns, 2001-2009 62
Table 43: HIV Therapeutics Market, Europe, Usage Patterns, 2009-2016 62
Table 44: HIV Therapeutics Market, Japan, Revenue ($m), 2001-2009 64
Table 45: HIV Therapeutics Market, Japan, Revenue ($m), 2009-2016 64
Table 46: HIV Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 65
Table 47: HIV Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016 65
Table 48: HIV Therapeutics Market, Japan, Diseased Population(’00), 2001-2009 66
Table 49: HIV Therapeutics Market, Japan, Diseased Population(’00), 2009-2016 66
Table 50: HIV Therapeutics Market, Japan, Treatment Seeking Population(’00), 2001-2009 67
Table 51: HIV Therapeutics Market, Japan, Treatment Seeking Population(’00), 2009-2016 67
Table 52: HIV Therapeutics Market, Japan, Diagnosis Population(’00), 2001-2009 68
Table 53: HIV Therapeutics Market, Japan, Diagnosis Population(’00), 2009-2016 68
Table 54: HIV Therapeutics Market, Japan, Prescription Population(’00), 2001-2009 69
Table 55: HIV Therapeutics Market, Japan, Prescription Population(’00), 2009-2016 69
Table 56: HIV Therapeutics Market, Japan, Usage Patterns(‘000), 2001-2009 70
Table 57: HIV Therapeutics Market, Japan, Usage Patterns, 2009-2016 71
Table 58: HIV Market, Global, Different Classes of Drugs 73
Table 59: HIV Therapeutics Market, Global, Pipeline Analysis, Phase I, 2009-2010 76
Table 60: HIV Therapeutics Market, Global, Pipeline Analysis, Phase II, 2009-2010 84
Table 61: HIV Therapeutics Market, Global, Pipeline Analysis, Phase III, 2009-2010 97
Table 62: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001-2009 106
Table 63: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2009-2016 106
Table 64: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 107
Table 65: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 107
Table 66: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 2001-2009 108
Table 67: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 2009-2016 109
Table 68: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2001-2009 118
Table 69: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2009-2016 118
Table 70: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2001-2009 120
Table 71: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2009-2016 120
Table 72: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2001-2009 121
Table 73: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2009-2016 121
Table 74: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (‘000), 2001-2009 122
Table 75: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (‘000), 2009-2016 123
Table 76: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2001-2009 128
Table 77: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2009-2016 128
Table 78: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2001-2009 130
Table 79: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2009-2016 130
Table 80: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2001-2009 131
Table 81: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2009-2016 131
Table 82: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2001-2009 132
Table 83: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2009-2016 133
Table 84: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 2001-2009 139
Table 85: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 2009-2016 139
Table 86: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2001-2009 142
Table 87: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2009-2016 142
Table 88: Hepatitis Therapeutics Market, US, Sales Value ($m), 2001-2009 144
Table 89: Hepatitis Therapeutics Market, US, Sales Value ($m), 2009-2016 144
Table 90: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 145
Table 91: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2009-2016 145
Table 92: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (‘000), 2001-2009 146
Table 93: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (‘000), 2009-2016 147
Table 94: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2001-2009 152
Table 95: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2009-2016 152
Table 96: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001-2009 154
Table 97: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009-2016 154
Table 98: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000), 2001-2009 155
Table 99: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000’s), 2009-2016 156
Table 100: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2001-2009 160
Table 101: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2009-2016 160
Table 102: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 161
Table 103: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016 161
Table 104: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2001-2009 162
Table 105: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2009-2016 163
Table 106: Hepatitis Therapeutics Market, Global, RandD Pipeline in Hepatitis B, 2010 172
Table 107: Hepatitis Therapeutics Market, Global, RandD Pipeline in Hepatitis C, 2010 177
Table 108: Herpes Simplex Therapeutics Market, Global, Revenues ($m), 2001-2009 192
Table 109: Herpes Simplex Therapeutics Market, Global, Market Forecast ($), 2009-2016 193
Table 110: Major Marketed Products Comparison in Herpes Simplex Market, 2010 200
Table 111: Simplex Therapeutics Market - Most Promising Drugs under Clinical Development, 2010 201
Table 112: Herpes Simplex Market - Phase III Clinical Pipeline, 2010 204
Table 113: Herpes Simplex Therapeutics Market - Phase II Clinical Pipeline, 2010 205
Table 114: Herpes Simplex Market - Phase I Clinical Pipeline, 2010 205
Table 115: Herpes Simplex Market - Discovery and Preclinical Pipeline, 2010 206
Table 116: Influenza Therapeutics Market Revenue, Global ($bn), 2001-2007e 209
Table 117: Influenza Therapeutics Market Revenue, Global ($bn), 2009-2016 209
Table 118: Influenza Therapeutics Market, Annual Cost of Therapy, Global ($), 2002-2009 210
Table 119: Influenza Therapeutics Market, Annual Cost of Therapy, Global ($), 2009-2016 210
Table 120: Influenza Therapeutics Market, Global, Diseased Population(Million), 2002-2009 211
Table 121: Influenza Therapeutics Market, Global, Diseased Population(Million), 2009-2016 211
Table 122: Influenza Therapeutics Market, Global, Treatment Seeking Population(Million), 2002-2009 212
Table 123:Influenza Therapeutics Market, Global, Treatment Seeking Population(Million), 2009-2016 212
Table 124: Influenza Therapeutics Market, Global, Diagnosis Population(Million), 2002-2009 213
Table 125: Influenza Therapeutics Market, Global, Diagnosis Population(Million), 2009-2016 213
Table 126: Influenza Therapeutics Market, Global, Diseased Population(Million), 2002-2009 214
Table 127: Influenza Therapeutics Market, Global, Diseased Population, 2009-2016 214
Table 128: Influenza Therapeutics Market, US, Revenues ($bn), 2001-2009 216
Table 129: Influenza Therapeutics Market, US, Revenues ($bn), 2009-2016 216
Table 130: InfluenzaTherapeutics Market, US, Annual Cost of Therapy ($), 2002-2009 217
Table 131: InfluenzaTherapeutics Market, US, Annual Cost of Therapy ($), 2009-2016 217
Table 132: Influenza Therapeutics, US, Diseased Population(Million), 2002-2009 218
Table 133: Influenza Therapeutics, US, Diseased Population(Million), 2009-2016 218
Table 134:Influenza Therapeutics Market, US, Treatment Seeking Population(Million), 2002-2009 219
Table 135:Influenza Therapeutics Market, US, Treatment Seeking Population(Million), 2009-2016 219
Table 136: Influenza Therapeutics Market, US, Diagnosis Population(Million), 2002-2009 220
Table 137: Influenza Therapeutics Market, US, Diagnosis Population(Million), 2009-2016 220
Table 138: Influenza Therapeutics Market, US, Usage Patterns(Million), 2002-2009 222
Table 139: Influenza Therapeutics Market, US, Usage Patterns(Million), 2009-2016 222
Table 140: Influenza Therapeutics Market, Europe, Revenues ($bn), 2001-2009 224
Table 141: Influenza Therapeutics Market, Europe, Revenues ($bn), 2009-2016 224
Table 142: Influenza Therapeutics Market, Europe, Average Cost of Treatment, 2002-2009 225
Table 143: Influenza Therapeutics Market, Europe, Average Cost of Treatment, 2009-2016 225
Table 144: Influenza Therapeutics Market, Europe, Diseased Population(Million), 2002-2009 226
Table 145: Influenza Therapeutics Market, Europe, Diseased Population(Million), 2009-2016 226
Table 146: Influenza Therapeutics Market, Europe, Treatment Seeking Population(Million), 2002-2009 227
Table 147: Influenza Therapeutics Market, Europe, Treatment Seeking Population(Million), 2009-2016 227
Table 148: Influenza Therapeutics Market, Europe, Diagnosis Population, 2002-2009 228
Table 149: Influenza Therapeutics Market, Europe, Diagnosis Population, 2009-2016 228
Table 150: Influenza Therapeutics Market, Europe, Usage Patterns(Million), 2002-2009 230
Table 151: Influenza Therapeutics Market, Europe, Usage Patterns(Million), 2009-2016 231
Table 152: Influenza Therapeutics Market, Japan, Revenues ($bn), 2001-2009 232
Table 153: Influenza Therapeutics Market, Japan, Revenues ($bn), 2009-2016 232
Table 154: Influenza Therapeutics Market, Japan, Average Cost of Treatment, 2002-2009 233
Table 155: Influenza Therapeutics Market, Japan, Average Cost of Treatment, 2009-2016 233
Table 156: Influenza Therapeutics Market, Japan, Diseased Population(Million), 2002-2009 234
Table 157: Influenza Therapeutics Market, Japan, Diseased Population(Million), 2002-2009 234
Table 158: Influenza Therapeutics Market, Japan, Treatment Seeking Population(Million), 2002-2009 235
Table 159: Influenza Therapeutics Market, Japan, Treatment Seeking Population(Million), 2002-2009 235
Table 160: Influenza Therapeutics Market, Japan, Diagnosis Population(Million), 2002-2009 236
Table 161: Influenza Therapeutics Market, Japan, Diagnosis Population(Million), 2009-2016 236
Table 162: Influenza Therapeutics Market, Japan, Usage Patterns(Million), 2002-2009 238
Table 163: Influenza Therapeutics Market, Japan, Usage Patterns(Million), 2009-2016 239
Table 164: Influenza Therapeutics Market, Global, Pipeline Analysis, Phase I, 2009-2010 240
Table 165: Influenza Therapeutics Market, Global, Pipeline Analysis, Phase II, 2009-2010 242
Table 166: Influenza Therapeutics Market, Global, Pipeline Analysis, Phase III, 2009-2010 245
Table 167: HIV Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2008 249
Table 168: BioAlliance Pharma - Herpes Pipeline Portfolio, February 2010 268
Table 169: Nutra Pharma Corporation - Herpes Pipeline Portfolio, 2010 269
Table 170: AiCuris GmbH and Co. KG - Herpes Simplex Pipeline Portfolio, 2010 270
Table 171: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical
Stage, 2008 275
Table 172: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008 276
Table 173: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III,
2008 276
Table 174: HIV Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008 277

1.2 List of Figures
Figure 1: HIV Therapeutics Market, Global, Market Overview, 2009 19
Figure 2: HIV Therapeutics Market, Global, Revenue ($m), 2000-2016 20
Figure 3: HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2000-2016 21
Figure 4: HIV Therapeutics Market, Global, Diseased Population, 2000-2016 23
Figure 5: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2016 25
Figure 6: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2016 27
Figure 7: HIV Therapeutics Market, Global, Prescription Population, 2000-2016 29
Figure 8: HIV Therapeutics Market, Global, Usage Patterns, 2000-2016 31
Figure 9: HIV Therapeutics Market, Global, Geographical Distribution of Revenues ($m),
2000-2016 33
Figure 10: HIV Therapeutics Market, US, Revenue ($m), 2000-2016 39
Figure 11: HIV Therapeutics Market, US, Annual Average Cost of Therapy ($), 2000-2016 41
Figure 12: HIV Therapeutics Market, US, Diseased Population,2000-2016 42
Figure 13: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2016 44
Figure 14: HIV Therapeutics Market, US, Diagnosis Population, 2000-2016 45
Figure 15: HIV Therapeutics Market, US, Prescription Population, 2000-2016 47
Figure 16: HIV Therapeutics Market, US, Usage Patterns, 2000-2016 49
Figure 17: HIV Therapeutics Market, Europe, Revenue ($m), 2000-2016 52
Figure 18: HIV Therapeutics Market, Europe, Average Cost of Treatment ($), 2000-2016 53
Figure 19: HIV Therapeutics Market, Europe, Diseased Population, 2000-2016 55
Figure 20: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2016 56
Figure 21: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2016 58
Figure 22: HIV Therapeutics Market, Europe, Prescription Population, 2000-2016 60
Figure 23: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2016 61
Figure 24: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2016 63
Figure 25: HIV Therapeutics Market, Japan, Annual Cost of Therapy ($), 2000-2016 65
Figure 26: HIV Therapeutics Market, Japan, Diseased Population, 2000-2016 66
Figure 27: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2016 67
Figure 28: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2016 68
Figure 29: HIV Therapeutics Market, Japan, Prescription Population, 2000-2016 69
Figure 30: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2016 70
Figure 31: HIV Therapeutics Market, Global, Pipeline by Phase and Class, 2009 75
Figure 32: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001-2016 106
Figure 33: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 107
Figure 34: Hepatitis Therapeutics Market, Global, Therapeutic Usage Patterns, 2001-2016 108
Figure 35: Hepatitis Therapeutics Market, Global, Diseases Population, 2001-2016 110
Figure 36: Hepatitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 111
Figure 37: Hepatitis Therapeutics Market, Global, Diagnosed Population, 2001-2016 112
Figure 38: Hepatitis Therapeutics Market, Global, Prescription Population, 2001-2016 113
Figure 39: Hepatitis B and Hepatitis C Therapeutic Market, Global, Branded and Generic Drugs (%), 2009 116
Figure 40: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2001-2016 118
Figure 41: Hepatitis Therapeutics Market, Global, Hepatitis B-Genotypes Based on Geographic Origins 119
Figure 42: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2001-2016 120
Figure 43: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($),
2001-2016 121
Figure 44: Hepatitis Market, Global, Hepatitis B Treatment Usage Patterns, 2001-2016 122
Figure 45: Hepatitis Market, Global, Hepatitis B Diseased Population, 2001-2016 123
Figure 46: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Seeking Population,
2001-2016 124
Figure 47: Hepatitis Market, Global, Hepatitis B Diagnosis Population, 2001-2016 125
Figure 48: Hepatitis Therapeutics Market, Global, Hepatitis B Prescription Population, 2001-2016 126
Figure 49: Hepatitis Therapeutics Market, Global, Hepatitis B Market Segmentation by Geography (%), 2009 and 2016 127
Figure 50: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2001-2016 128
Figure 51: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2001-2016 130
Figure 52: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($),
2001-2016 131
Figure 53: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns,
2001-2016 132
Figure 54: Hepatitis Therapeutics Market, Global, Hepatitis C Diseased Population, 2001-2016 134
Figure 55: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Seeking Population, 2001-2016 135
Figure 56: Hepatitis Therapeutics Market, Global, Hepatitis C Diagnosis Population, 2001-2016 136
Figure 57: Hepatitis Therapeutics Market, Global, Hepatitis C Prescription Population, 2001-2016 137
Figure 58: Hepatitis Therapeutics Market, Global, Hepatitis C Market Segmentation by Geography (%), 2009 and 2016 138
Figure 59: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation ($m), 2001-2016 139
Figure 60: Hepatitis Therapeutics Market, Global, Market Share by Geography (%), 2009 and 2016 141
Figure 61: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2001-2016 142
Figure 62: Hepatitis Therapeutics Market, US, Sales Value ($m), 2001-2016 144
Figure 63: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2016 145
Figure 64: Hepatitis Therapeutics Market, US, Treatment Usage Patterns, 2001-2016 146
Figure 65: Hepatitis Therapeutics Market, US, Diseased Population, 2001-2016 148
Figure 66: Hepatitis Therapeutics Market, US, Treatment Seeking Population, 2001-2016 149
Figure 67: Hepatitis Therapeutics Market, US, Diagnosed Population, 2001-2016 150
Figure 68: Hepatitis Therapeutics Market, US, Prescription Population, 2001-2016 151
Figure 69: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m),
2001-2016 152
Figure 70: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001-2016 154
Figure 71: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 2001-2016 155
Figure 72: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001-2016 156
Figure 73: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001-2016 157
Figure 74: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population, 2001-2016 158
Figure 75: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001-2016 159
Figure 76: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2001-2016 160
Figure 77: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2016 161
Figure 78: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2001-2016 162
Figure 79: Hepatitis Therapeutics Market, Japan, Diseased Population, 2001-2016 164
Figure 80: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016 165
Figure 81: Hepatitis Therapeutics Market, Japan, Diagnosed Population, 2001-2016 166
Figure 82: Hepatitis Therapeutics Market, Japan, Prescription Population, 2001-2016 167
Figure 83: Hepatitis Therapeutics Market, Global, RandD Pipeline by Indication (%), 2010 169
Figure 84: Hepatitis Therapeutics Market, Global, RandD Pipeline by Phase (%), 2010 170
Figure 85: Hepatitis Therapeutics Market, Global, RandD Pipeline by Phase in Hepatitis B Market (%), 2010 171
Figure 86: Hepatitis Therapeutics Market, Global, RandD Pipeline by Phase in Hepatitis C (%), 2010 176
Figure 87: Herpes Simplex Therapeutics Market, Global, Revenues ($bn), 2001-2009 192
Figure 88: Herpes Simplex Therapeutics Market, Global, Market Forecast ($bn), 2009-2016 193
Figure 89: S

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

  • $ 5 000
  • Industry report
  • April 2014
  • by Frost & Sullivan

The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.